Wall Street Zen Upgrades Bristol Myers Squibb to Strong Buy

Got story updates? Submit your updates here. ›

Wall Street Zen, an equity research firm, has upgraded its rating on Bristol Myers Squibb (NYSE: BMY) from Buy to Strong Buy. The upgrade comes as analysts see continued growth potential for the company's portfolio of cancer and immunology treatments, including several late-stage pipeline candidates.

Why it matters

Bristol Myers Squibb is one of the world's largest biopharmaceutical companies, with a focus on developing innovative therapies for serious diseases. The Strong Buy rating from Wall Street Zen suggests analysts believe the company's stock is undervalued and has significant upside potential, which could signal positive momentum for the business.

The details

In its research note, Wall Street Zen cited Bristol Myers Squibb's robust pipeline of oncology and immunology drugs as a key driver for the upgrade. The firm noted that several of the company's late-stage candidates, including potential treatments for various cancer types and autoimmune disorders, have shown promising results in clinical trials. This pipeline growth, combined with the company's established commercial products, is expected to fuel Bristol Myers Squibb's financial performance in the coming years.

• Wall Street Zen published its research note on Sunday, April 20, 2026.
• Bristol Myers Squibb is scheduled to pay a quarterly dividend of $0.63 per share on May 1, 2026, to shareholders of record as of April 2, 2026.

What they’re saying

What’s next

Investors will be closely watching Bristol Myers Squibb's upcoming earnings report and any updates on the company's pipeline development and regulatory approvals.